Compare KOS & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KOS | LBRX |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 475.3M | 533.1M |
| IPO Year | 2011 | 2025 |
| Metric | KOS | LBRX |
|---|---|---|
| Price | $0.94 | $22.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $2.72 | ★ $49.00 |
| AVG Volume (30 Days) | ★ 17.6M | 463.7K |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,392,234,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.47 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.87 | $13.36 |
| 52 Week High | $4.01 | $23.15 |
| Indicator | KOS | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 32.66 | N/A |
| Support Level | $0.87 | N/A |
| Resistance Level | $1.06 | N/A |
| Average True Range (ATR) | 0.09 | 0.00 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 21.98 | 0.00 |
Kosmos Energy Ltd is a deepwater exploration and production company focused on meeting the world's growing demand for energy. It has diversified oil and gas production from assets offshore Ghana, Equatorial Guinea, Mauritania, Senegal and the Gulf of America. The Company had operations in four geographic reporting segments: Ghana, Equatorial Guinea, Mauritania/Senegal and the Gulf of America. The majority of revenue is derived from the Ghana segment.
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.